The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005).
Ramesh K. Ramanathan
Research Funding - Merck
Shannon L McDonough
No relevant relationships to disclose
Hagen F. Kennecke
No relevant relationships to disclose
Syma Iqbal
No relevant relationships to disclose
Joaquina Celebre Baranda
No relevant relationships to disclose
Tara Elisabeth Seery
No relevant relationships to disclose
Howard John Lim
No relevant relationships to disclose
Aram F. Hezel
No relevant relationships to disclose
Gina M. Vaccaro
No relevant relationships to disclose
Charles David Blanke
No relevant relationships to disclose